Bioamber (BIOA) Tops Q4 EPS by 19c

Bioamber (NYSE: BIOA) reported Q4 EPS of ($0.20), $0.19 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $308 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Bioamber (BIOA) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
• Beam Global reports Q2 2026 revenue above $8.5M, up 170% from Q1
• AngioDynamics reports fiscal 2026 full-year net sales of $320M